Cytiva and Pear Bio Enhance Cancer Medicine Personalization with Innovative Single-Cell Approaches September 25, 2024: Cytiva, a global leader in life sciences and bioprocessing, and Pear Bio, company specialising in single-cell analysis technologies, have joined forces to advance personalised cancer treatment through
First-Ever Human Procedure for Graphene-Based Brain-Computer Interface Introduced by INBRAIN Neuroelectronics September 28, 2024: INBRAIN Neuroelectronics is a brain-computer interface therapeutics (BCI-Tx) specialising in graphene-based technologies, has announced the successful completion of the world’s first human procedure of its cortical
Neuralink’s New Blindsight Technology Receives FDA Approval September 20, 2024: Musk's brain-computer interface company, Neuralink, has announced that its latest innovation, Blindsight, has received licensing from the U.S. Food and Drug Administration (FDA). This
Exclusive Interview with Lore Gruenbaum, VP of Research for The Leukemia & Lymphoma Society's Therapy Acceleration Program Blood cancer continues to be a devastating disease, requiring ongoing research and support to advance treatments and improve access to care. Philanthropy plays a key role in driving innovation and
Insightful Session with Mathew Cook, Senior Director of Sales for the UK, Ireland, and Nordics at Merck Life Science In a recent interview, Mathew Cook, Senior Director Sales - UK, Ireland Nordics (Academia, Public & Pharma) at Merck Life Science | CSAM, talked with Muhammad Younis about the evolving landscape
Stem Cell Discovery Set to Revolutionise Bone Marrow Transplants September 2, 2024: Researchers at the Murdoch Children’s Research Institute in Melbourne and the University of Birmingham have achieved a major breakthrough in blood stem cell engineering. This innovative
London Biotechnology Show Makes Grand Return to Unveil Cutting-edge Advances in Health & Medicine The London Biotechnology Show returns for its highly anticipated second edition, building on the remarkable success of its debut. This year's event has significantly expanded its scope, offering
Successful Conclusion of London Biotechnology Show, Leaves Attendees Highly Satisfied May 9, London: The curtain has closed on the debut London Biotechnology Show 2024, leaving attendees thoroughly impressed by the seamless delivery of promised content and exhibits. From massive exhibition
London Biotechnology Show, Day 1 Wraps Up with Resounding Success Brewing with excitement, the London Biotechnology Show kicked off at Olympia West today, a two-day conference and expo, which brought together industry leaders, innovators, startups, investors and other important stakeholders
London Biotechnology Show Opens Its Doors Tomorrow at Olympia West London, May 7: The most-awaited London Biotechnology Show will finally open its doors tomorrow at Olympia West, London, UK. #LBS24 is a 2 day conference & exhibition that will host
London Biotechnology Show: Final Preparations Underway With Just One Week To Go! London, May 1: The countdown to the London Biotechnology Show 2024 is underway with just a week away until Olympia West opens its doors to this year’s most influential
Enlightening Session with Nava Whiteford, consultant at Whiteford Research Limited DNA sequencing has been crucial in deepening our comprehension of organisms' genetic composition, enabling the diagnosis of genetic disorders, and setting the stage for customized therapies. In a recent
University of Liverpool to Utilise Touchlight's dbDNA Technology in Neoantigen Cancer Vaccine Study. Hampton UK, 3 April 2024: Touchlight, a leading Contract Development and Manufacturing Organisation (CDMO) pioneering genetic medicine advancements through its innovative enzymatic doggybone DNA (dbDNA) technology, has announced a groundbreaking
Enlightening Session with Sam Tomlinson, Vice President of Global Drug Safety at Arriello. As biotechnology continues to rapidly transform the medical and healthcare realms, Pharmacovigilance finds itself challenged to match the speed of innovation in assessing the safety of emerging products entering the
Relation Therapeutics Secures $35 Million in New Seed Financing, Elevating Total Seed Funding to $60 Million March 14, 2024: Relation Therapeutics, the UK’s leading biotechnology firm pioneering the fusion of computational and experimental methodologies in drug discovery, has revealed a new round of seed financing,
